Alan Davis
Research Subjects
Alan Davis has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Annemarei Ranta
Department of Medicine, University of Otago, Wellington, New Zealand
7 shared publications - Peter Alan Barber
University of Auckland
6 shared publications - Valery L. Feigin
Auckland University of Technology
6 shared publications - Andrew Wilson
Department of Medicine, Wairau Hospital, Blenheim, New Zealand (A.W.).
5 shared publications - Dominique A. Cadilhac
Stroke and Critical Care Research, Florey Institute of Neuroscience and Mental Health, University of Mebourne, Heidelberg, Australia
5 shared publications - Hayley J. Denison
Centre for Public Health Research, Massey University, Wellington 6140, New Zealand
5 shared publications
Latest Publications
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e045260
Declining Incidence of Atrial Fibrillation–Associated Ischemic Stroke in Auckland, New Zealand (2012 Versus 2021)
Background: Atrial fibrillation (AF) is a major cause of ischemic stroke (IS), and this risk can be substantially reduced with oral anticoagulants (OACs). Using the population‐based ARCOS (Auckland Regional Community Stroke) study, we investigated the temporal trends in AF‐associated IS. Methods: We analyzed ARCOS IV (March 2011–February 2012) and ARCOS V (September 2020–August 2021). AF‐associated IS incidence was compared using Poisson exact methods. Regional OAC dispensing trends were also evaluated. Propensity score–weighted logistic regression estimated the marginal association between cohort and AF‐associated IS after standardizing for vascular risk factors. Interaction tests were performed for ethnicity, and sex‐specific differences were assessed using heterogeneity testing. OAC‐associated intracerebral hemorrhage rates were also examined. Results: Among 1694 (ARCOS IV) and 1982 (ARCOS V) IS cases, the proportion of AF‐associated IS declined from 32.4% to 21.5% (−10.8% [95% CI −13.7 to −8.0], P p =0.02 for heterogeneity). Temporal reductions differed by ethnicity, with greater decline in the “Other” ethnicity categories, but not in Māori or Pacific peoples. During the same period, patients dispensed OACs increased from 1094 to 1928 per 100 000 ( P <0.001). OAC‐associated intracerebral hemorrhage increased from 2.1 to 3.6 per 100 000, equating to 11 IS cases prevented per excess intracerebral hemorrhage. Conclusion: AF‐associated IS incidence declined in Auckland between 2012 and 2021, during a period of substantially increased community OAC use. Persistent ethnic inequities and sex‐specific variation highlight the need for improved AF detection, risk stratification, and prevention strategies.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e045260
Declining Incidence of Atrial Fibrillation–Associated Ischemic Stroke in Auckland, New Zealand (2012 Versus 2021)
Background: Atrial fibrillation (AF) is a major cause of ischemic stroke (IS), and this risk can be substantially reduced with oral anticoagulants (OACs). Using the population‐based ARCOS (Auckland Regional Community Stroke) study, we investigated the temporal trends in AF‐associated IS. Methods: We analyzed ARCOS IV (March 2011–February 2012) and ARCOS V (September 2020–August 2021). AF‐associated IS incidence was compared using Poisson exact methods. Regional OAC dispensing trends were also evaluated. Propensity score–weighted logistic regression estimated the marginal association between cohort and AF‐associated IS after standardizing for vascular risk factors. Interaction tests were performed for ethnicity, and sex‐specific differences were assessed using heterogeneity testing. OAC‐associated intracerebral hemorrhage rates were also examined. Results: Among 1694 (ARCOS IV) and 1982 (ARCOS V) IS cases, the proportion of AF‐associated IS declined from 32.4% to 21.5% (−10.8% [95% CI −13.7 to −8.0], P p =0.02 for heterogeneity). Temporal reductions differed by ethnicity, with greater decline in the “Other” ethnicity categories, but not in Māori or Pacific peoples. During the same period, patients dispensed OACs increased from 1094 to 1928 per 100 000 ( P <0.001). OAC‐associated intracerebral hemorrhage increased from 2.1 to 3.6 per 100 000, equating to 11 IS cases prevented per excess intracerebral hemorrhage. Conclusion: AF‐associated IS incidence declined in Auckland between 2012 and 2021, during a period of substantially increased community OAC use. Persistent ethnic inequities and sex‐specific variation highlight the need for improved AF detection, risk stratification, and prevention strategies.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2836-2845
Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use
BACKGROUND: Intravenous thrombolysis (IVT) in patients with recent ingestion of direct oral anticoagulants (DOACs) is a frequent challenge and remains controversial. The benefit of DOAC reversal before IVT is uncertain. METHODS: Using target trial methodology, we analyzed data from 28 comprehensive stroke centers. Patients on DOACs were included if they met IVT criteria, had a National Institutes of Health Stroke Scale score of ≥2, and last DOAC intake within 48 hours or was undeterminable. Safety and efficacy outcomes (symptomatic intracerebral hemorrhage, any intracerebral hemorrhage, major bleeding, 90-day mortality, and good functional outcome [modified Rankin Scale score of 0–2 or return to baseline]) were compared between those receiving IVT versus no IVT and IVT with versus without reversal. In addition, a comparison was made with patients from the New Zealand stroke registry, all of whom underwent reversal with idarucizumab. We adjusted for covariates known to be associated with safety and efficacy outcomes, including age, stroke severity, intended thrombectomy, blood glucose, blood pressure, DOAC reversal, and time from last intake. RESULTS: Overall, 1342 patients fulfilled the target trial criteria. The median age was 80 (interquartile range, 73–86) years, median National Institutes of Health Stroke Scale score was 11, 50% were female, and 52% of patients received endovascular therapy. IVT was given in 342 of 1342 (25%) patients. Of these, 141 (41.2%) had verified DOAC intake <12 hours before admission, and 92 (26.9%) within 12 to 24 hours. Symptomatic intracerebral hemorrhage occurred in 10 of 328 (3.0%) of patients receiving IVT and 54 of 921 (5.9%) patients not receiving IVT (adjusted difference, −2.1% [95% CI, −5.3% to +1.2]). Patients receiving IVT were more likely to have good functional outcomes (adjusted difference, +14.4% [95% CI, +7.1% to +21.8%]). Comparing 289 patients with reversal (from the additional New Zealand registry) and 283 patients without reversal before IVT (from the target trial population), there was no significant difference in symptomatic intracerebral hemorrhage, major bleeding, or efficacy outcomes. CONCLUSIONS: This target trial confirms previous observational data regarding the safety of off-label IVT in patients with recent DOAC intake. More data and dedicated trials are needed for patients with confirmed high DOAC plasma levels and regarding the efficacy and safety of DOAC reversal before IVT.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2836-2845
Intravenous Thrombolysis in Patients With Recent Intake of Direct Oral Anticoagulants: A Target Trial Analysis and Comparison With Reversal Agent Use
BACKGROUND: Intravenous thrombolysis (IVT) in patients with recent ingestion of direct oral anticoagulants (DOACs) is a frequent challenge and remains controversial. The benefit of DOAC reversal before IVT is uncertain. METHODS: Using target trial methodology, we analyzed data from 28 comprehensive stroke centers. Patients on DOACs were included if they met IVT criteria, had a National Institutes of Health Stroke Scale score of ≥2, and last DOAC intake within 48 hours or was undeterminable. Safety and efficacy outcomes (symptomatic intracerebral hemorrhage, any intracerebral hemorrhage, major bleeding, 90-day mortality, and good functional outcome [modified Rankin Scale score of 0–2 or return to baseline]) were compared between those receiving IVT versus no IVT and IVT with versus without reversal. In addition, a comparison was made with patients from the New Zealand stroke registry, all of whom underwent reversal with idarucizumab. We adjusted for covariates known to be associated with safety and efficacy outcomes, including age, stroke severity, intended thrombectomy, blood glucose, blood pressure, DOAC reversal, and time from last intake. RESULTS: Overall, 1342 patients fulfilled the target trial criteria. The median age was 80 (interquartile range, 73–86) years, median National Institutes of Health Stroke Scale score was 11, 50% were female, and 52% of patients received endovascular therapy. IVT was given in 342 of 1342 (25%) patients. Of these, 141 (41.2%) had verified DOAC intake <12 hours before admission, and 92 (26.9%) within 12 to 24 hours. Symptomatic intracerebral hemorrhage occurred in 10 of 328 (3.0%) of patients receiving IVT and 54 of 921 (5.9%) patients not receiving IVT (adjusted difference, −2.1% [95% CI, −5.3% to +1.2]). Patients receiving IVT were more likely to have good functional outcomes (adjusted difference, +14.4% [95% CI, +7.1% to +21.8%]). Comparing 289 patients with reversal (from the additional New Zealand registry) and 283 patients without reversal before IVT (from the target trial population), there was no significant difference in symptomatic intracerebral hemorrhage, major bleeding, or efficacy outcomes. CONCLUSIONS: This target trial confirms previous observational data regarding the safety of off-label IVT in patients with recent DOAC intake. More data and dedicated trials are needed for patients with confirmed high DOAC plasma levels and regarding the efficacy and safety of DOAC reversal before IVT.
- 1 March 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (3) , 848-856
Comparison of Stroke Care Costs in Urban and Nonurban Hospitals and Its Association With Outcomes in New Zealand: A Nationwide Economic Evaluation
Background: Although geographical differences in treatment and outcomes after stroke have been described, we lack evidence on differences in the costs of treatment between urban and nonurban regions. Additionally, it is unclear whether greater costs in one setting are justified given the outcomes achieved. We aimed to compare costs and quality-adjusted life years in people with stroke admitted to urban and nonurban hospitals in New Zealand. Methods: Observational study of patients with stroke admitted to the 28 New Zealand acute stroke hospitals (10 in urban areas) recruited between May and October 2018. Data were collected up to 12 months poststroke including treatments in hospital, inpatient rehabilitation, other health service utilization, aged residential care, productivity, and health-related quality of life. Costs in New Zealand dollars were estimated from a societal perspective and assigned to the initial hospital that patients presented to. Unit prices for 2018 were obtained from government and hospital sources. Multivariable regression analyses were conducted when assessing differences between groups. Results: Of 1510 patients (median age 78 years, 48% female), 607 presented to nonurban and 903 to urban hospitals. Mean hospital costs were greater in urban than nonurban hospitals ($13 191 versus $11 635, P =0.002), as were total costs to 12 months ($22 381 versus $17 217, P P <0.001). Differences in costs and quality-adjusted life years remained between groups after adjustment. Depending on the covariates included, costs per additional quality-adjusted life year in the urban hospitals compared to the nonurban hospitals ranged from $65 038 (unadjusted) to $136 125 (covariates: age, sex, prestroke disability, stroke type, severity, and ethnicity). Conclusions: Better outcomes following initial presentation to urban hospitals were associated with greater costs compared to nonurban hospitals. These findings may inform greater targeted expenditure in some nonurban hospitals to improve access to treatment and optimize outcomes.
- 1 March 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (3) , 848-856
Comparison of Stroke Care Costs in Urban and Nonurban Hospitals and Its Association With Outcomes in New Zealand: A Nationwide Economic Evaluation
Background: Although geographical differences in treatment and outcomes after stroke have been described, we lack evidence on differences in the costs of treatment between urban and nonurban regions. Additionally, it is unclear whether greater costs in one setting are justified given the outcomes achieved. We aimed to compare costs and quality-adjusted life years in people with stroke admitted to urban and nonurban hospitals in New Zealand. Methods: Observational study of patients with stroke admitted to the 28 New Zealand acute stroke hospitals (10 in urban areas) recruited between May and October 2018. Data were collected up to 12 months poststroke including treatments in hospital, inpatient rehabilitation, other health service utilization, aged residential care, productivity, and health-related quality of life. Costs in New Zealand dollars were estimated from a societal perspective and assigned to the initial hospital that patients presented to. Unit prices for 2018 were obtained from government and hospital sources. Multivariable regression analyses were conducted when assessing differences between groups. Results: Of 1510 patients (median age 78 years, 48% female), 607 presented to nonurban and 903 to urban hospitals. Mean hospital costs were greater in urban than nonurban hospitals ($13 191 versus $11 635, P =0.002), as were total costs to 12 months ($22 381 versus $17 217, P P <0.001). Differences in costs and quality-adjusted life years remained between groups after adjustment. Depending on the covariates included, costs per additional quality-adjusted life year in the urban hospitals compared to the nonurban hospitals ranged from $65 038 (unadjusted) to $136 125 (covariates: age, sex, prestroke disability, stroke type, severity, and ethnicity). Conclusions: Better outcomes following initial presentation to urban hospitals were associated with greater costs compared to nonurban hospitals. These findings may inform greater targeted expenditure in some nonurban hospitals to improve access to treatment and optimize outcomes.
- 5 September 2022
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 45 (18) , 2957-2963
Patient, carer and health worker perspectives of stroke care in New Zealand: a mixed methods survey
It is important to understand how consumers (person with stroke/family member/carer) and health workers perceive stroke care services.Consumers and health workers from across New Zealand were surve...
- 5 September 2022
- Published by Taylor & Francis in Disability and Rehabilitation
- Vol. 45 (18) , 2957-2963
Patient, carer and health worker perspectives of stroke care in New Zealand: a mixed methods survey
It is important to understand how consumers (person with stroke/family member/carer) and health workers perceive stroke care services.Consumers and health workers from across New Zealand were surve...
- Open Access
- 26 July 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (4) , e414-e426
Geographic Disparities in Stroke Outcomes and Service Access
Background and Objectives International evidence shows that patients treated at nonurban hospitals experience poorer access to key stroke interventions. Evidence for whether this results in poorer outcomes is conflicting and generally based on administrative or voluntary registry data. The aim of this study was to use prospective high-quality comprehensive nationwide patient-level data to investigate the association between hospital geography and outcomes of patients with stroke and access to best-practice stroke care in New Zealand. Methods This is a prospective, multicenter, nationally representative observational study involving all 28 New Zealand acute stroke hospitals (18 nonurban) and affiliated rehabilitation and community services. Consecutive adults admitted to the hospital with acute stroke between May 1 and October 31, 2018, were captured. Outcomes included functional outcome (modified Rankin Scale [mRS] score shift analysis), functional independence (mRS score 0–2), quality of life (EuroQol 5-dimension, 3-level health-related quality of life questionnaire), stroke/vascular events, and death at 3, 6, and 12 months and proportion accessing thrombolysis, thrombectomy, stroke units, key investigations, secondary prevention, and inpatient/community rehabilitation. Results were adjusted for age, sex, ethnicity, stroke severity/type, comorbid conditions, baseline function, and differences in baseline characteristics. Results Overall, 2,379 patients were eligible (mean [SD] age 75 [13.7] years; 51.2% male; 1,430 urban, 949 nonurban). Patients treated at nonurban hospitals were more likely to score in a higher mRS score category (greater disability) at 3 (adjusted odds ratio [aOR] 1.28, 95% CI 1.07–1.53), 6 (aOR 1.33, 95% CI 1.07–1.65), and 12 (aOR 1.31, 95% CI 1.06–1.62) months and were more likely to have died (aOR 1.57, 95% CI 1.17–2.12) or experienced recurrent stroke and vascular events at 12 months (aOR 1.94, 95% CI 1.14–3.29 and aOR 1.65, 95% CI 1.09–2.52). Fewer nonurban patients received recommended stroke interventions, including endovascular thrombectomy (aOR 0.25, 95% CI 0.13–0.49), acute stroke unit care (aOR 0.60, 95% CI 0.49–0.73), antiplatelet prescriptions (aOR 0.72, 95% CI 0.58–0.88), ≥60 minutes of daily physical therapy (aOR 0.55, 95% CI 0.40–0.77), and community rehabilitation (aOR 0.69, 95% CI 0.56–0.84). Discussion Patients managed at nonurban hospitals experience poorer stroke outcomes and reduced access to key stroke interventions across the entire care continuum. Efforts to improve access to high quality stroke care in nonurban hospitals should be a priority.
- 26 July 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (4) , e414-e426
Open AccessGeographic Disparities in Stroke Outcomes and Service Access
Background and Objectives International evidence shows that patients treated at nonurban hospitals experience poorer access to key stroke interventions. Evidence for whether this results in poorer outcomes is conflicting and generally based on administrative or voluntary registry data. The aim of this study was to use prospective high-quality comprehensive nationwide patient-level data to investigate the association between hospital geography and outcomes of patients with stroke and access to best-practice stroke care in New Zealand. Methods This is a prospective, multicenter, nationally representative observational study involving all 28 New Zealand acute stroke hospitals (18 nonurban) and affiliated rehabilitation and community services. Consecutive adults admitted to the hospital with acute stroke between May 1 and October 31, 2018, were captured. Outcomes included functional outcome (modified Rankin Scale [mRS] score shift analysis), functional independence (mRS score 0–2), quality of life (EuroQol 5-dimension, 3-level health-related quality of life questionnaire), stroke/vascular events, and death at 3, 6, and 12 months and proportion accessing thrombolysis, thrombectomy, stroke units, key investigations, secondary prevention, and inpatient/community rehabilitation. Results were adjusted for age, sex, ethnicity, stroke severity/type, comorbid conditions, baseline function, and differences in baseline characteristics. Results Overall, 2,379 patients were eligible (mean [SD] age 75 [13.7] years; 51.2% male; 1,430 urban, 949 nonurban). Patients treated at nonurban hospitals were more likely to score in a higher mRS score category (greater disability) at 3 (adjusted odds ratio [aOR] 1.28, 95% CI 1.07–1.53), 6 (aOR 1.33, 95% CI 1.07–1.65), and 12 (aOR 1.31, 95% CI 1.06–1.62) months and were more likely to have died (aOR 1.57, 95% CI 1.17–2.12) or experienced recurrent stroke and vascular events at 12 months (aOR 1.94, 95% CI 1.14–3.29 and aOR 1.65, 95% CI 1.09–2.52). Fewer nonurban patients received recommended stroke interventions, including endovascular thrombectomy (aOR 0.25, 95% CI 0.13–0.49), acute stroke unit care (aOR 0.60, 95% CI 0.49–0.73), antiplatelet prescriptions (aOR 0.72, 95% CI 0.58–0.88), ≥60 minutes of daily physical therapy (aOR 0.55, 95% CI 0.40–0.77), and community rehabilitation (aOR 0.69, 95% CI 0.56–0.84). Discussion Patients managed at nonurban hospitals experience poorer stroke outcomes and reduced access to key stroke interventions across the entire care continuum. Efforts to improve access to high quality stroke care in nonurban hospitals should be a priority.
- Open Access
- 3 January 2022
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 20, 100358
The impact of ethnicity on stroke care access and patient outcomes: a New Zealand nationwide observational study
- 3 January 2022
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 20, 100358
Open AccessThe impact of ethnicity on stroke care access and patient outcomes: a New Zealand nationwide observational study
- Open Access
- 12 January 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (1) , e25374
Reducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care): Protocol for a Nationwide Observational Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Stroke systems of care differ between larger urban and smaller rural settings and it is unclear to what extent this may impact on patient outcomes. Ethnicity influences stroke risk factors and care delivery and patient outcomes in non-stroke settings. Little is known about the impact of ethnicity on post-stroke care especially in Māori and Pacific populations. Objective: To describe the study protocol for the Reducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care) Study Methods: This large nationwide observational study assesses the impact of rurality and ethnicity on best practice stroke care access and outcomes involving all 28 New Zealand hospitals caring for stroke patients capturing every stroke patient admitted to hospital during the 2017-2018 study period. In addition, it explores current access barriers through consumer focus groups, and consumer, carer, clinician, manager, and policy maker surveys. It also assesses economic impact of care provided at different types of hospitals and to different ethnicities, as well as exploring cost-efficacy of individual interventions and care bundles. Finally it compares manual study data collection to routine health administrative data, and explores the feasibility of developing outcome models using only administrative data and the cost-efficacy of using additional manually collected registry data. Sample size estimates: Part 1a - 2,400 participants to identify a 10% difference between up to four geographic sub-groups at 90% power with alpha 0.05 and 10-20% loss to follow-up. Part 1b - 7,645 to include an estimated 850 Māori and 419 Pacific patients to provide >90% and >80% power respectively. Part 2 – fifty patient/carer surveys, forty provider surveys, and ten focus groups to achieve saturation of themes. Study outcome(s): Main outcome is modified Rankin Score at 3 months (mRS). Secondary outcomes include mRS, EQ-5D-3L, stroke recurrence, vascular events, death, and readmission at 3, 6, and 12 months as well as cost of care and themes around access barriers. Results: The study is underway with national and institutional ethics approval in place, 2,379 patients recruited for part 1a, 6,837 for part 1b, ten focus groups conducted, and 70 surveys completed. Data collection is essentially completed including follow-up assessment, however, primary and secondary analyses, data linkage, data validation, and health economics analysis still underway. Conclusions: The methods of this study may provide the basis for future epidemiological studies to guide care improvements in other countries and populations.
- 12 January 2021
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 10 (1) , e25374
Open AccessReducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care): Protocol for a Nationwide Observational Study
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Stroke systems of care differ between larger urban and smaller rural settings and it is unclear to what extent this may impact on patient outcomes. Ethnicity influences stroke risk factors and care delivery and patient outcomes in non-stroke settings. Little is known about the impact of ethnicity on post-stroke care especially in Māori and Pacific populations. Objective: To describe the study protocol for the Reducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care) Study Methods: This large nationwide observational study assesses the impact of rurality and ethnicity on best practice stroke care access and outcomes involving all 28 New Zealand hospitals caring for stroke patients capturing every stroke patient admitted to hospital during the 2017-2018 study period. In addition, it explores current access barriers through consumer focus groups, and consumer, carer, clinician, manager, and policy maker surveys. It also assesses economic impact of care provided at different types of hospitals and to different ethnicities, as well as exploring cost-efficacy of individual interventions and care bundles. Finally it compares manual study data collection to routine health administrative data, and explores the feasibility of developing outcome models using only administrative data and the cost-efficacy of using additional manually collected registry data. Sample size estimates: Part 1a - 2,400 participants to identify a 10% difference between up to four geographic sub-groups at 90% power with alpha 0.05 and 10-20% loss to follow-up. Part 1b - 7,645 to include an estimated 850 Māori and 419 Pacific patients to provide >90% and >80% power respectively. Part 2 – fifty patient/carer surveys, forty provider surveys, and ten focus groups to achieve saturation of themes. Study outcome(s): Main outcome is modified Rankin Score at 3 months (mRS). Secondary outcomes include mRS, EQ-5D-3L, stroke recurrence, vascular events, death, and readmission at 3, 6, and 12 months as well as cost of care and themes around access barriers. Results: The study is underway with national and institutional ethics approval in place, 2,379 patients recruited for part 1a, 6,837 for part 1b, ten focus groups conducted, and 70 surveys completed. Data collection is essentially completed including follow-up assessment, however, primary and secondary analyses, data linkage, data validation, and health economics analysis still underway. Conclusions: The methods of this study may provide the basis for future epidemiological studies to guide care improvements in other countries and populations.
- Open Access
- 16 November 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Reducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care): Protocol for a Nationwide Observational Study (Preprint)
BACKGROUND Stroke systems of care differ between larger urban and smaller rural settings and it is unclear to what extent this may impact on patient outcomes. Ethnicity influences stroke risk factors and care delivery as well as patient outcomes in nonstroke settings. Little is known about the impact of ethnicity on poststroke care, especially in Māori and Pacific populations. OBJECTIVE Our goal is to describe the protocol for the Reducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care) study. METHODS This large, nationwide observational study assesses the impact of rurality and ethnicity on best practice stroke care access and outcomes involving all 28 New Zealand hospitals caring for stroke patients, by capturing every stroke patient admitted to hospital during the 2017-2018 study period. In addition, it explores current access barriers through consumer focus groups and consumer, carer, clinician, manager, and policy-maker surveys. It also assesses the economic impact of care provided at different types of hospitals and to patients of different ethnicities and explores the cost-efficacy of individual interventions and care bundles. Finally, it compares manual data collection to routine health administrative data and explores the feasibility of developing outcome models using only administrative data and the cost-efficacy of using additional manually collected registry data. Regarding sample size estimates, in Part 1, Study A, 2400 participants are needed to identify a 10% difference between up to four geographic subgroups at 90% power with an α value of .05 and 10% to 20% loss to follow-up. In Part 1, Study B, a sample of 7645 participants was expected to include an estimated 850 Māori and 419 Pacific patients and to provide over 90% and over 80% power, respectively. Regarding Part 2, 50% of the patient or carer surveys, 40 provider surveys, and 10 focus groups were needed to achieve saturation of themes. The main outcome is the modified Rankin Scale (mRS) score at 3 months. Secondary outcomes include mRS scores; EQ-5D-3L (5-dimension, 3-level EuroQol questionnaire) scores; stroke recurrence; vascular events; death; readmission at 3, 6, and 12 months; cost of care; and themes around access barriers. RESULTS The study is underway, with national and institutional ethics approvals in place. A total of 2379 patients have been recruited for Part 1, Study A; 6837 patients have been recruited for Part 1, Study B; 10 focus groups have been conducted and 70 surveys have been completed in Part 2. Data collection has essentially been completed, including follow-up assessment; however, primary and secondary analyses, data linkage, data validation, and health economics analysis are still underway. CONCLUSIONS The methods of this study may provide the basis for future epidemiological studies that will guide care improvements in other countries and populations. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/25374
- 16 November 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessReducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care): Protocol for a Nationwide Observational Study (Preprint)
BACKGROUND Stroke systems of care differ between larger urban and smaller rural settings and it is unclear to what extent this may impact on patient outcomes. Ethnicity influences stroke risk factors and care delivery as well as patient outcomes in nonstroke settings. Little is known about the impact of ethnicity on poststroke care, especially in Māori and Pacific populations. OBJECTIVE Our goal is to describe the protocol for the Reducing Ethnic and Geographic Inequities to Optimise New Zealand Stroke Care (REGIONS Care) study. METHODS This large, nationwide observational study assesses the impact of rurality and ethnicity on best practice stroke care access and outcomes involving all 28 New Zealand hospitals caring for stroke patients, by capturing every stroke patient admitted to hospital during the 2017-2018 study period. In addition, it explores current access barriers through consumer focus groups and consumer, carer, clinician, manager, and policy-maker surveys. It also assesses the economic impact of care provided at different types of hospitals and to patients of different ethnicities and explores the cost-efficacy of individual interventions and care bundles. Finally, it compares manual data collection to routine health administrative data and explores the feasibility of developing outcome models using only administrative data and the cost-efficacy of using additional manually collected registry data. Regarding sample size estimates, in Part 1, Study A, 2400 participants are needed to identify a 10% difference between up to four geographic subgroups at 90% power with an α value of .05 and 10% to 20% loss to follow-up. In Part 1, Study B, a sample of 7645 participants was expected to include an estimated 850 Māori and 419 Pacific patients and to provide over 90% and over 80% power, respectively. Regarding Part 2, 50% of the patient or carer surveys, 40 provider surveys, and 10 focus groups were needed to achieve saturation of themes. The main outcome is the modified Rankin Scale (mRS) score at 3 months. Secondary outcomes include mRS scores; EQ-5D-3L (5-dimension, 3-level EuroQol questionnaire) scores; stroke recurrence; vascular events; death; readmission at 3, 6, and 12 months; cost of care; and themes around access barriers. RESULTS The study is underway, with national and institutional ethics approvals in place. A total of 2379 patients have been recruited for Part 1, Study A; 6837 patients have been recruited for Part 1, Study B; 10 focus groups have been conducted and 70 surveys have been completed in Part 2. Data collection has essentially been completed, including follow-up assessment; however, primary and secondary analyses, data linkage, data validation, and health economics analysis are still underway. CONCLUSIONS The methods of this study may provide the basis for future epidemiological studies that will guide care improvements in other countries and populations. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/25374